PROM1 and neoplasm: Previous studies have proposed that LCSCs exhibit heightened resistance to sorafenib[29] and that the response of HCC patients to sorafenib treatment associates with CD133 expression within the tumor.[30] We hypothesized that circRAPGEF1 might influence sorafenib sensitivity in HCC.